Life Sciences

FDA warns AstraZeneca for alleged off-label promotion

Pharma Compliance Alert, December 10, 2008

An AstraZeneca sales representative allegedly promoted the company’s antipsychotic Seroquel and Seroquel XL for an off-label use during an unsolicited sales call with a physician, according to an FDA warning letter.

Post a Comment

Name:

 

E-mail:

 

Please enter your comment below:

   

Please enter the text below:

   
   

Most Popular